We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Shire Pulls European Application for Daytrana
The item has been added to your shopping cart.
Shire Pulls European Application for Daytrana
March 16, 2009
Shire has withdrawn its EU marketing authorization application for Daytrana to treat attention deficit hyperactivity disorder (ADHD), citing European regulators’ request to conduct an additional clinical trial in a European population.